-
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07137338 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362 ·
Phase: Phase 2 ·
Ages: 40 Years to 84 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
A Study Investigating the Impact of IMT With CR On Exercise Responses In HF
NCT07086131 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Study Of Acute Decompensated Heart Failure
NCT07572955 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
NCT07093528 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
NCT07083011 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Study of Paramedic HF Management
NCT06874556 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
A Study to Evaluate Breathing Muscle Training in Cardiac Rehab
NCT04984473 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
NCT06033950 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis, Rochester, Saint Paul
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
AI-Guided Left Bundle Branch Area Pacing
NCT07206602 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371 ·
Phase: Phase 2 ·
Ages: 40 Years to 85 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)
NCT07559903 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Alleviant ALLAY-HF Study
NCT05685303 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Alleviant ALLAY-HFrEF Study
NCT06812533 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
NCT05647213 ·
Phase: Phase 1 ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
NCT06762964 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
CCM OPEN HF Registry
NCT07112924 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
COMPARE-VENT Feasibility Pilot Study
NCT07656259 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)
NCT05996328 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 60 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Community-Informed Interventions for Equitable Congestive Heart Failure Management in Primary Care
NCT07730827 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume
NCT06195059 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
ELEVATE-HFpEF Clinical Study
NCT06678841 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
NCT06507657 ·
Phase: Early Phase 1 ·
Ages: 60 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
NCT04592445 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction
NCT07401771 ·
Phase: Not specified ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515 ·
Phase: Phase 3 ·
Ages: 22 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
NCT06425848 ·
Phase: Not specified ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Minnesota: Maplewood, Minneapolis
-
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
NCT05873634 ·
Phase: Not specified ·
Ages: 30 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
His Bundle Pacing in Bradycardia and Heart Failure
NCT03008291 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
NCT06039176 ·
Phase: Not specified ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Inspiratory Muscle Training in HFpEF
NCT06510231 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398 ·
Phase: Phase 3 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis, Rochester
-
Left vs Left Randomized Clinical Trial
NCT05650658 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Minnesota: Mankato, Maplewood, Minneapolis
-
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
NCT06517186 ·
Phase: Not specified ·
Ages: 30 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708 ·
Phase: Not specified ·
Ages: 14 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
NCT06228924 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis, Saint Cloud
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404 ·
Phase: Not specified ·
Ages: 0 Years to 20 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060 ·
Phase: Phase 3 ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Minnesota: Mankato, Minneapolis
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Minnesota: Coon Rapids, Minneapolis, Robbinsdale, Rochester
-
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368 ·
Phase: Not specified ·
Ages: 18 Years to 105 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis, Rochester, Saint Cloud
-
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
NCT06360380 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 21 Years to 79 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Rilonacept in Subjects With Cardiac Sarcoidosis
NCT06660732 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Duluth, Saint Cloud
-
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
NCT07131631 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
NCT06271577 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652 ·
Phase: Phase 3 ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis, Saint Paul
-
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
NCT03142152 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Saint Cloud
-
The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)
NCT06702501 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 30 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT07221851 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis, Saint Paul
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis, Rochester
-
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
NCT06641362 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
NCT05459233 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Voice Analysis for Monitoring Patients With Heart Failure
NCT06566911 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester